Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$67,592.00
Total Gain % 103.70%
Total Gain $17,592.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
33 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $67,592.00
Total Gain $17,592.00
(103.70%)
Value $34,557.00
Close Price (13 Dec) $113.30
Unrealised P/L (%) 103.70%
Unrealised P/L $17,592.00
Total $67,592.00
$17,592.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $62.17
Added Price $43.06
STRIDE Rating 39
Value Change (%) 44.40%
Current Price $32.40
Added Price $34.64
STRIDE Rating 23
Value Change (%) -6.47%
Current Price $20.02
Added Price $29.27
STRIDE Rating 36
Value Change (%) -31.59%
Total Buy0
Total Hold0
Total Sell3
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

ABIVAX S.A.

ABIVAX S.A.
Pharmaceuticals, Biotechnology and Life Sciences : Biotechnology.
ABVX on Euronext Paris.
Price in Euro, all financial data originally reported in Euro.
The business last filed accounts on the 20 Sep, 2016.
Company website: www.abivax.com
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
France, Micro Cap
Market Capitalisation: €64.08M
Total Enterprise Value: Get a demo
ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases primarily in Asia, Australia, and New Zealand. Its principal products include ABX464, a small molecule inhibiting HIV replication that is in Phase IIa clinical trials; ABX203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX196, an adjuvant candidate that has completed Phase I clinical trials for vaccination based on iNKT agonists. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis. In addition, the company’s pre-clinical programs comprise ABX220, an anti-viral candidate for the treatment of Dengue fever; ABX544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and ABX309, an anti-viral candidate for the treatment of Chikungunya. ABIVAX Société Anonyme has strategic partnerships with Heber Biotec and Vacunas Finlay. The company is headquartered in Paris, France. Read More
Price & Valuation Info
Price Quote on 15th Dec '16
€6.51 -0.13(-1.96%)
52 Week Range
3.87
18.03
Interactive STRIDE chart with history.
Only available to subscribers.
Get a demo now.
Performance
1 month -0.29 (-4.26%)
year-to-date -7.64 (-53.99%)
1 year -7.99 (-55.1%)
Show More Valuation Info
Momentum
vs 52week high 36%
vs 50d SMA 92%
vs 200d SMA84%
STRIDE Valuations
Consider Buy Get a demo
Fair Value Get a demo
Consider Sell Get a demo
Price/Adj. Earnings Get a demo
Price/Adj FCF Get a demo
Price/Adj. TBV Get a demo
Forecast Growth Get a demo
Other Valuations
Price/Book Get a demo
Price/Tangible Book Get a demo
Price/Sales Get a demo
Price/Earnings Get a demo
Price/Free Cashflow Get a demo
EV/EBITDA Get a demo
Dividend Yield Get a demo
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Get a demo
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more